Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Avalyn Pharma Inc.

Avalyn Completes Successful Phase 1 Clinical Trials of AP02, its Novel Inhaled Formulation of Nintedanib, Preparing for Phase 2 Development in Idiopathic Pulmonary Fibrosis
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Participate in TD Cowen 45th Annual Health Care Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Participate in Multiple Upcoming Investor Conferences
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Appoints Heather Turner, J.D., Biopharma Industry Veteran, as Chair of its Board of Directors
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Participate in Multiple Upcoming Investor Conferences
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn CEO Lyn Baranowski Named a PharmaVoice 100 Honoree
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Announces Upcoming Presentations on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the 22nd International Colloquium on Lung and Airway Fibrosis
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Presents Multiple Posters on AP01 for Pulmonary Fibrosis, Including MIST Phase 2b Trial Design and ATLAS Phase 1b Study Post-hoc Analyses, at ERS 2024
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Announces Initiation of its Global Phase 2b MIST Study of AP01 Inhaled Pirfenidone for Progressive Pulmonary Fibrosis
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Participate in Multiple Upcoming Investor Conferences
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Announces Upcoming Presentations on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the European Respiratory Society International Congress 2024
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Announces Initiation of Phase 1b Clinical Study for AP02, its Novel Inhaled Nintedanib
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Participate in Multiple Upcoming Investor Conferences
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Participate in Jefferies Global Healthcare Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Presents Clinical Data on AP01 for Pulmonary Fibrosis, Including Long-Term Efficacy and Imaging Biomarker Data, at ATS 2024
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Announces Multiple Presentations on its Lead Program, AP01, for Pulmonary Fibrosis and its Approach to Developing Novel Inhaled Therapies for Lung Diseases at the 2024 American Thoracic Society International Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Bolsters Leadership Team with the Appointment of Douglas Carlson as Chief Financial Officer and Chief Business Officer
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Participate in Leerink Partners Global Biopharma Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Participate in Multiple Upcoming Investor Conferences
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Participate in the 2023 RBC Capital Markets Healthcare Private Company Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Presents Data from its AP01 and AP02 Inhaled Therapeutics Programs for Pulmonary Fibrosis
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Strengthens Leadership Team with Key Appointments, including Dr. Craig Conoscenti as SVP, Clinical Development, and Jim Bishop as SVP, Business Operations
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Participate in Multiple Upcoming Investor Conferences
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn to Provide Keynote Presentation at the Formulation & Delivery U.S. 2023 Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Pharma’s CEO Leads Workshop on Clinical Strategy at IPF Summit
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Pharma Presents Data Showing Favorable Tolerability and Potential of AP01 to Preserve Forced Vital Capacity in Adults with Pulmonary Fibrosis
From Avalyn Pharma Inc.
Via GlobeNewswire
Avalyn Pharma Appoints Business Operations Leader, Melissa Rhodes, to the Role of Chief Operating Officer
From Avalyn Pharma Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.